Mon premier blog

Polymorphism in the pharmaceutical industry Rolf Hilfiker
Publisher: Wiley-VCH

Comprehensive reference for researchers in the field of cancer pharmacogenomics and clinicians, from both academia and industry; Provides a collection of multi-disciplinary topics; Covers the most important aspects of pharmacogenomics applied to cancer patients. In his painstakingly 275-page decision, the single judge, Justice Manmohan Singh opined that the generic product Erlocip manufactured and sold by Cipla contains polymorphic B variant of Erlotinib hydrochloride as active ingredient and hence do not infringed the compound per se claims of the It is likely that the reasoning of this decision may add yet another disappointment and further dismay for the pharmaceutical companies in enforcing their patents in India . Noted that “we plan to take the lead in providing the pharmaceutical and biotechnology industry with well-characterized, predictive biomarker panels composed of both genetic polymorphisms and gene expression patterns. Take any tiny hint that someone with a certain polymorphism responds badly to a particular drug, and industry will claim the gene is bad, not the drug. The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. CrystEngComm will publish a themed issue on 'Crystal engineering and crystallography in the pharmaceutical industry' in early 2012 with Guest Editors Dr Magali Hickey, Dr Örn Almarsson and Dr Matt Peterson. Operation design for controlling polymorphism in the anti-solvent crystallization by using ternary phase diagram. Operation Anti-solvent or drowning-out crystallization is widely used in the pharmaceutical industry for high yield production. Considering the amount of substrates it deals with, it is surprising that the pharmaceutical industry probably neglect the enzyme when testing new drugs for bad reactions. Over the last twenty years, an enormous amount of effort has been expended by both the pharmaceutical industry and academia towards developing more powerful techniques and screening assays to identify the metabolic profiles and enzymes involved in drug These efforts are made in order to avoid latestage drug failure due to such factors as undesirable metabolic instability, toxic metabolites, drug-drug interactions, or polymorphic and saturation metabolism. Could exert a profound effect on the solid-state properties of that system, the pharmaceutical industry is required to take a strong interest in polymorphism and solvatomorphism as per the regulations laid down by the regulatory authorities.